# US 2016/0257933 A1 · Xeno-free generation of tissue-specific progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257933 A1
- Document ID: US20160257933A1
- Status: Published application
- Kind: A1
- Application number: 15/154,653
- Filed: 2016-05-13
- Published: 2016-09-08
- Earliest claimed: 2010-09-13
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Peiman Hematti; Jaehyup Kim
- Web page: https://patentgrep.com/patent/US20160257933A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0676: {Pancreatic cells}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 5/0694: {Cells of blood, e.g. leukemia cells, myeloma cells}
- G01N 33/5073: {Stem cells}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2502/1157: Monocytes, macrophages
- C12N 2502/1358: Bone marrow mesenchymal stem cells (BM-MSC)
- C12N 2506/02: from embryonic cells
- C12N 2506/22: from pancreatic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.

## Claims

### Claim at position 1

-4. (canceled)

### Claim 5

A population of tissue-specific progenitor cells produced by a method comprising the steps of:
co-culturing a CD14+ cell, a tissue-specific mesenchymal stem cell (MSC), and a pluripotent cell in vitro until the pluripotent cell differentiates into the desired tissue-specific progenitor cell.

### Claim 6 (depends on 5)

The population of tissue-specific progenitors of claim 5, wherein the MSC and CD14+ cell are syngeneic with regard to each other.

### Claim 7

A cell culture composition comprising a CD14+ cell, a tissue-specific MSC, and a pluripotent cell.

### Claim 8 (depends on 7)

The cell culture composition of claim 7, wherein the CD14+ cell and the MSC are syngeneic with regard to each other.

### Claim 9

A cell culture composition comprising a CD14+ cell, a tissue-specific MSC, a pluripotent cell, and a tissue-specific progenitor cell.

### Claim 10

A method of treating a disorder associated with aberrant loss of normal cell function comprising the step of administering to an individual in need thereof a tissue-specific progenitor cell produced by a method comprising the steps of:
co-culturing a CD14+ cell, a tissue-specific mesenchymal stem cell (MSC), and a pluripotent cell in vitro until the pluripotent cell differentiates into the desired tissue-specific progenitor cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the progenitor cell is administered by injection.

### Claim 12 (depends on 10)

The method of claim 10, wherein the progenitor cell is administered by topical application.

### Claim 13 (depends on 10)

The method of claim 10, wherein the progenitor cell is syngeneic with regard to the individual.

### Claim 14 (depends on 10)

The method of claim 10, wherein the progenitor cell is allogeneic with regard to the individual.

### Claim 15

A method of in vitro screening for compounds that modulate tissue-specific progenitor cells, the method comprising the steps of:
co-culturing a CD14+ cell, a tissue-specific MSC, and a pluripotent cell in vitro until the pluripotent cell differentiates into the desired tissue-specific progenitor cell; and
contacting the progenitor cell with the compound.

### Claim 16 (depends on 15)

The method of claim 15, wherein the progenitor cell is cultured under differentiating conditions.

### Claim 17 (depends on 15)

The method of claim 15, wherein the MSC is a bone marrow-derived MSC.

### Claim 18

A method of in vitro screening for compounds that modulate tissue-specific progenitor cell development, the method comprising the steps of:
co-culturing a CD14+ cell, a tissue-specific MSC, and a pluripotent cell in vitro in the presence of the compound.

### Claim 19

A method for culturing a malignant cell in vitro, the method comprising the step of:
co-culturing the malignant cell with a CD14+ cell such that the malignant cell proliferates.

### Claim 20 (depends on 19)

The method of claim 19, wherein the CD14+ cell is an MSC-educated macrophage.

### Claim 21 (depends on 19)

The method of claim 19, wherein the malignant cell is co-cultured with the CD14+ cell in the presence of an MSC.

### Claim 22 (depends on 19)

The method of claim 19, wherein the malignant cell is isolated from a human individual.

### Claim 23 (depends on 19)

The method of claim 19, wherein the malignant cell is a multiple myeloma cell.

### Claim 24

A cell culture composition comprising a CD14+ cell, an MSC, and a malignant cell.

### Claim 25

A method for culturing a CD34+ cell in vitro, the method comprising the step of:
co-culturing a CD34+ cell with a CD14+ cell in vitro such that the CD34+ cell proliferates.

### Claim 26 (depends on 25)

The method of claim 25, wherein the CD14+ cell is an MSC-educated macrophage.

### Claim 27 (depends on 25)

The method of claim 25, wherein the CD34+ cell is co-cultured with the CD14+ cell in the presence of an MSC.
